Terran Biosciences will develop and commercialize two late-stage CNS candidates developed by Sanofi under a new deal as it aims to address unmet needs in the neuropsychiatry space.
Cryptic Terran Licences Advanced CNS Assets From Sanofi
Deal Value Under Wraps
The US biotech has nabbed a couple of Sanofi’s Phase III CNS candidates, its third deal of the year aimed at transforming the neuropsychiatry market.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.